A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

• Status: Completed
• Trial end date: 2017-05-15
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Advanced or metastatic cancer.

• Able to swallow tablets.

• For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer with KRAS and/or BRAF mutations.

• Discontinued all previous treatments for cancer and recovered from the acute effects from the therapy.

Exclusion Criteria:

• Active infection (fungal, viral, or bacterial).

• Active cancer in your brain or spinal cord.

• Acute or chronic leukemia.

• Serious heart condition.

• Disease that requires immunosuppressant therapy.

• Diagnosis of inflammatory bowel disease.

• Major small bowel resection that interferes with your body's ability to absorb the oral medicine.

• Participated in other clinical trials investigating prexasertib or ralimetinib.

• Pregnant or breastfeeding.

• Other pre-existing conditions or medical history which your doctor will explain to you.